Future Research Priorities for Morbidity Control of Lymphedema

BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Indian J Dermatol
Autors principals: Narahari, S R, Aggithaya, Madhur Guruprasad, Moffatt, Christine, Ryan, T J, Keeley, Vaughan, Vijaya, B, Rajendran, P, Karalam, S B, Rajagopala, S, Kumar, N K, Bose, K S, Sushma, K V
Format: Artigo
Idioma:Inglês
Publicat: Medknow Publications & Media Pvt Ltd 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5286751/
https://ncbi.nlm.nih.gov/pubmed/28216723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0019-5154.198039
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars